Rare-disease targets from the mechanism you know, not the platforms you can't afford.

Turn your rare-disease mechanism into a ranked target list.

For a CSO closing a seed round on a single mechanism: get a defensible candidate list built only on published data—in 10 to 12 weeks, without the €2M platform license.

Start your target model See what's included →

10–12 WEEKS · €85,000 FIXED · PUBLISHED DATA ONLY

The situation

One mechanism, no ranked targets yet.

You've closed funding on a rare-disease lead. Your mechanism is published, your data consents are clean, and your team understands exactly why this target matters. What you don't have is a ranked list of candidates you can take to lead selection. Recursion and BenevolentAI will give you breadth—five mechanisms, three tissues, a thousand data points—wrapped in a platform license that costs €2M and takes six months to stand up. You needed focus.

Mechanism-first discovery requires either six-figure platform licenses or building a bioinformatics team in-house.
Broad-spectrum platforms impose a breadth tax: you pay for off-target signals and features your mechanism doesn't need.
Without structured prioritization, early biotech teams defend target choices to boards with publication dates and intuition.

The model

A disease-specific model built on your mechanism alone.

The Disease-Specific Target Model takes the one mechanism your team understands—the published literature, the consented data, the science you bet your round on—and builds a ranked list of 20 to 30 candidates scored for mechanistic fit and druggability. Single-mechanism rigor, delivered in 10 to 12 weeks, without platform overhead or breadth noise.

Built only on published and consented data—no proprietary black boxes, no structural prediction alone.
Ranked by mechanistic scoring, not statistical correlations across unrelated mechanisms.
Documented for internal IP records and regulatory readiness from day one.

Schematic blueprint diagram of a molecular pathway network with one node enlarged and marked as the top-ranked candidate target

Deliverables

What the model gives you.

You receive a ranked candidate list, a detailed literature gap analysis, two structured workshops with your R&D lead, and a 30-day support window. Everything is documented for IP and board reporting.

01

Ranked list of 20 to 30 targets scored for mechanistic fit and druggability—defensible to your board and ready for lead selection.
02

Literature gap analysis that highlights under-explored pathways within your mechanism, surfacing novel hypotheses your team may have missed.
03

Two workshops with your CSO or R&D team to validate rankings, refine mechanism assumptions, and align on next steps.
04

Model documentation suitable for internal IP records, grant applications, and regulatory submissions—structured knowledge, not a locked platform.

Timeline

How it works: 10 to 12 weeks.

You submit your mechanism focus, available data, and key publications. We build a model, run the ranking, and deliver findings in structured workshops where your team validates and shapes the output. The process is transparent; you're not waiting for a black-box result.

Week 1–2

mechanism briefing, data review, literature scope definition.
Week 3–8

model training, target ranking, druggability assessment.
Week 9–10

delivery, structured workshops, findings validation with your team.
Weeks 11–12

documentation finalization, post-delivery questions, transition to lead selection.

The trade-off

Why this is not a platform.

Platforms

Platforms sell breadth. They integrate dozens of data sources, model multiple mechanisms, and support any tissue. That power costs €2M, takes six months to configure, and gives you answers you didn't ask for.

Mechanism

The Disease-Specific Target Model does the opposite: it takes your one mechanism, your published data, your consented cohorts, and builds a single ranked list. No multi-target overhead. No feature creep. No platform license. Just the mechanism you know, turned into a ranked list you can defend.

Mechanism-specific scoring optimizes for depth and fidelity; platform breadth adds noise to focused discovery.
Deliverables ship as structured artifacts you own and control—no vendor onboarding or IT integration required.
Fixed project fee with no recurring costs, no platform seats, no annual maintenance burden.

Diligence

The rigor you can defend.

The model is trained only on published literature and consented data—nothing proprietary, nothing black-box. Rankings are mechanistic: each target is scored on pathway fit, data support, and druggability evidence. Your team reviews and validates in two structured workshops before the findings are final. The output is documented in detail for internal records, grant submissions, and IP protection—the standards early biotech uses to prove diligence to boards and regulators.

Mechanism-first scoring: targets ranked by fit to your specific mechanism, not statistical associations across unrelated targets.
Published-data only: every candidate traceable to literature or your consented data; nothing hidden in structural prediction.
Defensible to your board: findings documented and workshop-validated, not vendor claims.
Ready for grants and regulatory review: model documentation meets institutional IP and diligence standards.

Fixed fee

Fixed project fee: €85,000.

The Disease-Specific Target Model is €85,000, fixed. No platform seats. No annual license. No variable costs. You pay once; you get a ranked target list, a literature map, two workshops, and a 30-day support window. That's the entire cost. No spreadsheet surprises, no vendor upsell after week two.

Disease-Specific Target Model

€85,000

10 to 12 weeks

Full disease-specific discovery model trained only on published and consented data for the target mechanism
Ranked list of 20 to 30 candidate targets with mechanistic scoring and druggability assessment
Literature gap analysis highlighting under-explored pathways within the mechanism
Two structured review workshops with the CSO or R&D team
Model documentation package suitable for internal IP records and grant reporting
30-day post-delivery window for follow-up scientific questions

Start your target model

Questions

Common questions answered.

Most CSOs ask whether the model can expand to other mechanisms, whether outputs are suitable for partnerships, and whether they own the results. Yes to all. Reach out with any other question—we respond within two business days.

Can we expand the model to other mechanisms later?

Yes. This covers one; a second mechanism is a second engagement.

Do we own the model outputs?

Yes. Rankings, gap analysis, and documentation are yours for partnerships and IP filings.

Is 10 to 12 weeks realistic for single-mechanism focus?

Yes, because we model only your mechanism with no multi-mechanism overhead.

What if we need help after delivery?

You have 30 days of follow-up questions included; ongoing support beyond that is separate.

Start here

Ready to turn your mechanism into a ranked target list?